Uniqsis expands LED photoreactor range

3 Mar 2019

The availability of three new alternative switchable LED configurations provides chemists with the unique ability to optimally undertake almost any photochemistry reaction.

Uniqsis announces its PhotoSyn high-power photoreactor light module for continuous flow chemistry is now available with alternative LED array configurations that makes it compatible with a broader range of photochemical reactions.

Uniqsis expands LED photoreactor range

The availability of three new alternative switchable LED configurations (blue, UVA-blue and blue-green-white) provides chemists with the unique ability to optimally undertake almost any photochemistry reaction. The operating wavelengths of the three LED array configurations are blue (455 nm), blue-green-white (455 nm, 530 nm and 420-700 nm) and UVA-blue (365 nm and 455 nm).

The curved, water-cooled LED arrays in the PhotoSyn are designed to maximise photon intensity and concentrate the available light on the independently temperature controlled central coil reactor. These high-quality LED’s have lifetimes of several years in continuous use without suffering a significant reduction in intensities.

The PhotoSyn incorporates a cooling fan to minimise undesirable radiative heating of the flow reactor whilst being cleverly engineered to completely prevent potentially hazardous light emissions from the unit, thereby avoiding the need to operate the instrument in a shielded enclosure. Moreover, the PhotoSyn is protected with safety interlocks that deactivate the light source and protect the user if any attempt is made to remove the cover whilst in use.

The PhotoSyn is compatible with both the Uniqsis Cold Coil standalone reactor module and the Polar Bear Plus Flow cryogenic flow reactor, which control the coil reactor temperature independently of the lamps. Reactions may be run from 150 °C down to sub-ambient temperatures dependent upon the power of the cooling unit used. The variable power supply allows the lamp power output to be adjusted from 10-100% making the unit suitable for both small scale R&D and scale up applications.

Read More

Related news

Follicum files patent application for new topical formulation for hair loss

Follicum files patent application for new topical formulation for hair loss

30 Apr 2019

Using easy-to-apply cream instead of direct scalp injection would extend patent protection by 8 years.

Read more 
Hovione Technology acquires global rights to new pulmonary inhaler device

Hovione Technology acquires global rights to new pulmonary inhaler device

15 Apr 2019

The Papillon DPI is a single-part, blister-based, reusable inhaler, suitable for both chronic and acute treatments.

Read more 
Isotype-specific secondary antibodies for improved signal detection

Isotype-specific secondary antibodies for improved signal detection

10 Apr 2019

Offers an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.

Read more 
Sterling Pharma to acquire CiVentiChem in the US

Sterling Pharma to acquire CiVentiChem in the US

9 Apr 2019

The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.

Read more 
Catalent expands OptiMelt hot melt extrusion capabilities

Catalent expands OptiMelt hot melt extrusion capabilities

4 Apr 2019

The investment includes the addition of equipment to enhance development capabilities for preclinical and early clinical phase development, as well as adding downstream processing technologies to support HME formulations.

Read more 
'Drugs from bugs' joint venture

'Drugs from bugs' joint venture

4 Apr 2019

Lonza and Chr. Hansen create a strategic joint venture to become the partner of choice for developing and manufacturing live biotherapeutic products for pharma and biotech customers.

Read more 
Curcumin and pomegrantes - new hope for Alzheimer’s prevention?

Curcumin and pomegrantes - new hope for Alzheimer’s prevention?

3 Apr 2019

New research at University of Warwick will test how curcumin kick-starts the brain’s cleansing of damaging plaques and cells.

Read more 
MedPharm's appointment with Destiny

MedPharm's appointment with Destiny

28 Mar 2019

Global contract provider to develop new XF-platform drug formulations for the treatment of a number of topically treated infections, including diabetic foot ulcers and ophthalmic infections.

Read more 
Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

13 Mar 2019

Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.

Read more 
Envigo launches PATHWAY to enable FIH clinical trials

Envigo launches PATHWAY to enable FIH clinical trials

11 Mar 2019

PATHWAY manages the complexity of the entire safety assessment process on behalf of the company’s pharmaceutical and biotechnology customers.

Read more